title: Caulerpenyne binding to tubulin: structural modifications by a non conventional pharmacological agent.
abstract: The most widely used molecules in cancer chemotherapy are Vinca-alkaloids and Taxoids, numerous chemists attempted the synthesis of analogs which bind to their well-known tubulin pharmacological site. Unfortunately, tumors develop resistance to these compounds; therefore the definition of anchoring points and potential binding sites for new drugs on tubulin is of major interest. Caulerpenyne (Cyn), the major secondary metabolite synthesized by the green marine alga Caulerpa taxifolia could be one of these drugs, since it inhibits the assembly of tubulin and MTP (Barbier et al., 2001). We observed that the tubulin-Cyn complex is poorly reversed. Cyn did not bind to sulfhydryl groups and the measure of the extent of binding is 1.6 +/- 0.2 suggesting two potential binding sites. Then, we demonstrated by competition measurements that Cyn did not interact to colchicine, Taxol and Vinca-alkaloid binding domain. Finally, mass spectrometric analysis of proteolytic cleavage of tubulin-Cyn complex demonstrated that Cyn did not bind covalently to tubulin and evidenced two good candidate regions for Cyn binding, one on alpha-tubulin and the other on beta-tubulin.
authors.affiliation: INSERM UMR 911 CRO2 ; Aix-Marseille Université, Faculté de Pharmacie, 27 bd Jean Moulin, 13385 Marseille Cedex 05, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Bourdron
authors.forename: Pascale
authors.initials: P
authors.lastname: Barbier
authors.forename: Diane
authors.initials: D
authors.lastname: Allegro
authors.forename: Claude
authors.initials: C
authors.lastname: Villard
authors.forename: Daniel
authors.initials: D
authors.lastname: Lafitte
authors.forename: Laurent
authors.initials: L
authors.lastname: Commeiras
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Parrain
authors.forename: Vincent
authors.initials: V
authors.lastname: Peyrot
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000378:metabolism; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism; D001665:Binding Sites; D001667:Binding, Competitive; D003078:Colchicine / Q000737:chemistry / Q000378:metabolism; D047630:Depsipeptides / Q000737:chemistry / Q000378:metabolism; D007536:Isomerism; D007769:Lactams / Q000737:chemistry / Q000378:metabolism; D007783:Lactones / Q000737:chemistry / Q000378:metabolism; D008870:Microtubules / Q000737:chemistry / Q000378:metabolism / Q000648:ultrastructure; D008958:Models, Molecular; D017239:Paclitaxel / Q000737:chemistry / Q000378:metabolism; D011485:Protein Binding; D011487:Protein Conformation; D012717:Sesquiterpenes / Q000737:chemistry* / Q000378:metabolism; D012756:Sheep; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013438:Sulfhydryl Compounds / Q000737:chemistry; D017186:Titrimetry; D014357:Trypsin / Q000737:chemistry; D014404:Tubulin / Q000737:chemistry* / Q000378:metabolism; D014461:Ultracentrifugation
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D047630:Depsipeptides; D007769:Lactams; D007783:Lactones; D012717:Sesquiterpenes; D013438:Sulfhydryl Compounds; D014404:Tubulin; C097889:caulerpenyne; D014357:Trypsin; C114033:cryptophycin 52; D017239:Paclitaxel; D003078:Colchicine